FEDERAL PRISONS in BC will be VISITED by HepCBC TEAM June 10-14, 2019

Twice a year HepCBC's all-volunteer outreach team visits the Community Resource Expo (CRE) events held in BC's federal prisons to give the most recent information about viral hepatitis (B and C) care and prevention, and to offer support to those seeking treatment. To see profiles of these institutions, go to https://www.csc-scc.gc.ca/institutions/001002-5000-eng.shtml Our all-volunteer team consists of Leon Anderson, Ron Larsen, Dr. Sofia Bartlett, Chery

BLUEPRINT for ELIMINATING HEPATITIS C in CANADA

Is it possible to ELIMINATE HEPATITIS C in Canada? Dr. Jordan Feld presents the BLUEPRINT: "Blueprint to inform hepatitis C elimination efforts in Canada" at CanHepC's launch session, May 24, 2019 Dr Jordan Feld presents the Blueprint to inform hepatitis C elimination efforts in Canada at the 8th Canadian Symposium on Hepatitis C Virus/Canadian Liver Meeting on May 24th, 2019 in Montreal. Watch and share this moving one-hour presentation at https://www.

FDA approves first treatment for all HCV genotypes in CHILDREN (USA)

FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada's children, we hope Canada will soon follow (Canada's version of AbbVie's hepatitis C drug is spelled Maviret™)! For Immediate Release, April 30, 2019 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients

FREE Seminar in HCV Elimination among Men Who Have Sex with Men (MSM)

Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Men Who Have Sex with Men [MSM] - ACCESS INFORMATION BELOW Persons Who Inject Drugs [PWID] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The MSM module is introduced below... CCO CME/CE-certified interactive video module

FREE Seminar in HCV Elimination among Persons Who Inject Drugs (PWID)

Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Persons Who Inject Drugs, [PWID] - ACCESS INFORMATION BELOW. Men Who Have Sex with Men [MSM] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The PWID module is introduced below... CCO CME/CE-certified interactive video modu

The Week in Review: Jan. 25, 2019 – Feb. 22, 2019

Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring

No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring Protocols?

Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV. HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca

The Week in Review: Nov 2 – Nov 9, 2018

Friday, Nov 9, 2018 News Recap: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program. High Prevalence of Cirrhosis in Adults with Chronic...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa

The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...